...
首页> 外文期刊>The Journal of Veterinary Medical Science >Gastrointestinal and Hematologic Adverse Events after Administration of Vincristine, Cyclophosphamide, and Doxorubicin in Dogs with Lymphoma that Underwent a Combination Multidrug Chemotherapy Protocol
【24h】

Gastrointestinal and Hematologic Adverse Events after Administration of Vincristine, Cyclophosphamide, and Doxorubicin in Dogs with Lymphoma that Underwent a Combination Multidrug Chemotherapy Protocol

机译:长春新碱,环磷酰胺和阿霉素在接受联合多药化疗方案的淋巴瘤犬中给药后的胃肠道和血液学不良事件

获取原文
           

摘要

References(11) Cited-By(5) The present study aimed to objectively evaluate the adverse events after the administration of chemotherapeutic agents used in the University of Wisconsin (UW)-Madison chemotherapy protocol (UW-25) for canine lymphoma, using the Veterinary Co-operative Oncology Group common terminology criteria for adverse events (VCOG-CTCAE). The medical records of 40 dogs with multicentric high-grade lymphoma that underwent UW-25 were reviewed. Gastrointestinal adverse events of grade 2 and above and blood/bone marrow adverse events of all grades were evaluated. Gastrointestinal adverse events occurring at least once during the entire period of UW-25 were observed in 50% (20/40), 17.9% (7/39), and 8.1% (3/37) of the dogs after the administration of vincristine (VCR), cyclophosphamide (CPA), and doxorubicin (DXR), respectively. Blood/bone marrow adverse events occurring at least once during UW-25 were observed in 57.5% (23/40), 41% (16/39), and 8.1% (3/37) of the dogs after the administration of VCR, CPA, and DXR, respectively. The rate of patients that experienced gastrointestinal adverse events was higher after the first administration of VCR than after the first administration of DXR. Findings obtained in this study will be helpful in predicting the adverse events that could occur when dogs with lymphoma are treated with UW-25.
机译:参考文献(11)引用(5)本研究旨在客观评估威斯康星大学(UW)-麦迪逊大学化学治疗方案(UW-25)使用犬类淋巴瘤的化疗药物后的不良事件。兽医合作肿瘤小组不良事件的通用术语标准(VCOG-CTCAE)。回顾了40例接受UW-25治疗的多中心高级别淋巴瘤犬的病历。评估2级及以上的胃肠道不良事件和所有等级的血液/骨髓不良事件。在服用长春新碱后,在UW-25整个期间,至少有一次发生胃肠道不良事件,分别占50%(20/40),17.9%(7/39)和8.1%(3/37)的狗(VCR),环磷酰胺(CPA)和阿霉素(DXR)。服用VCR后,在UW-25期间至少发生过一次血液/骨髓不良事件,分别占57.5%(23/40),41%(16/39)和8.1%(3/37)的狗, CPA和DXR。第一次服用VCR后经历胃肠道不良事件的患者发生率高于第一次服用DXR后。这项研究中获得的发现将有助于预测用UW-25治疗淋巴瘤犬时可能发生的不良事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号